The ACCURATE-PRO study is an investigator-initiated, prospective, multicenter, observational, real-world cohort study. The core objective in managing chronic coronary syndrome (CCS) is to identify clinically significant myocardial ischemia to guide treatment decisions and improve long-term prognosis. While coronary computed tomography angiography (CCTA) is a crucial non-invasive anatomical imaging tool, it has limitations in determining the functional significance of coronary stenosis. Computed tomography-derived fractional flow reserve (CT-FFR) provides this functional assessment non-invasively based on CCTA images. However, there is a lack of systematic, prospective, multicenter evidence regarding its clinical value in risk stratification, treatment decision support, and prognostic evaluation for a continuous, real-world spectrum of CCS patients in China.
This study aims to evaluate the relationship between abnormal CT-FFR results and the risk of 1-year major adverse clinical events in CCS patients undergoing CCTA and CT-FFR. The study hypothesizes that abnormal CT-FFR is associated with a higher risk of 12-month major adverse clinical events, and that CT-FFR results are significantly correlated with subsequent treatment strategies, providing important value in risk stratification and mid-to-long-term prognosis.
The trial plans to consecutively enroll approximately 3,000 patients across multiple clinical centers in China. Eligible participants must be 18 years or older, have a clinical diagnosis of CCS, and have successfully obtained CT-FFR results following a CCTA examination. Patients will be excluded if they have acute coronary syndrome (such as STEMI, NSTEMI, or acute unstable angina), unanalyzable CT-FFR results/image quality, or non-cardiac conditions limiting their life expectancy to less than one year.
Since this is an observational study, it will not alter routine clinical care pathways or assign interventions. The primary exposure factor analyzed will be the lowest CT-FFR result per patient, comparing an abnormal CT-FFR group (≤ 0.80) to a normal CT-FFR group (\> 0.80).
Participants will be followed up via telephone, outpatient visits, or hospitalization at 6, 12, 24, and 60 months after enrollment. The primary endpoint is a composite of all-cause death, myocardial infarction (MI), or ischemia-driven revascularization within 1 year after enrollment. Key secondary endpoints include the occurrence of the primary endpoint at 24 and 60 months, target vessel failure (a composite of cardiac death, target vessel MI, or target vessel revascularization), stroke, health economics analysis, and the association between CT plaque characteristics and clinical outcomes.
Age ≥ 18 years.
Clinical diagnosis of chronic coronary syndrome (CCS).
Completed coronary computed tomography angiography (CCTA) examination and successfully obtained CT-derived fractional flow reserve (CT-FFR) results.
The subject or their legal representative voluntarily participates in this study and has signed the written informed consent form.
Acute coronary syndrome (ACS), including ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI), or acute episodes of unstable angina.
Unable to obtain valid CT-FFR results, or the image quality is insufficient to support analysis.
Pregnant patients or those who intend to become pregnant during the study period.
Non-cardiac comorbidities indicating a life expectancy of less than one year.
The study population consists of patients with chronic coronary syndrome (CCS) who undergo coronary computed tomography angiography (CCTA) and CT-derived fractional flow reserve (CT-FFR) evaluation as part of their routine clinical care. Participants are consecutively recruited from multiple tertiary medical centers across China to ensure a representative real-world cohort. This population reflects the broad clinical spectrum of CCS patients encountered in actual practice, encompassing a wide range of coronary disease severity as assessed by non-invasive functional imaging.
Cohort
Prospective
Not listed
Composite of All-cause Death, Myocardial Infarction (MI), or Ischemia-driven Revascularization
The primary endpoint is defined as the composite occurrence of all-cause death, myocardial infarction (MI), or ischemia-driven revascularization.
Primary Endpoint Excluding Periprocedural MI
The primary composite endpoint of all-cause death, myocardial infarction, or ischemia-driven revascularization, excluding periprocedural myocardial infarction.
Composite of All-cause Death, Myocardial Infarction (MI), or Ischemia-driven Revascularization
The primary endpoint is defined as the composite occurrence of all-cause death, myocardial infarction (MI), or ischemia-driven revascularization.
Individual Components of the Primary Endpoint
The occurrence of the individual components of the primary composite endpoint, analyzed separately. These include all-cause death, myocardial infarction, and ischemia-driven revascularization.
Target Vessel Failure (TVF)
A composite endpoint including cardiac death, target vessel myocardial infarction (MI), or target vessel revascularization.
Click on the lead sponsor to view all of their trials.
